Erasing iatrogenic neoantigens from in vivo CRISPR screens

Fei Yi; Christopher A Klebanoff

doi:10.1016/j.immuni.2021.02.017

Erasing iatrogenic neoantigens from in vivo CRISPR screens

Immunity. 2021 Mar 9;54(3):406-408. doi: 10.1016/j.immuni.2021.02.017.

Authors

Fei Yi¹, Christopher A Klebanoff²

Affiliations

¹ Human Oncology and Pathogenesis Program, Immuno-Oncology Service, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA; Center for Cell Engineering, MSKCC, New York, NY 10065, USA.
² Human Oncology and Pathogenesis Program, Immuno-Oncology Service, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA; Center for Cell Engineering, MSKCC, New York, NY 10065, USA; Parker Institute for Cancer Immunotherapy, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA. Electronic address: [email protected].

PMID: 33691131
DOI: 10.1016/j.immuni.2021.02.017

Abstract

In vivo genetic screens using CRISPR-Cas9 are a powerful tool to resolve the molecular determinants of response and resistance to cancer immunotherapies; however, vector immunogenicity can introduce artifact. In this issue of Immunity, Dubrot et al. report a strategy to "erase" vector-associated neoantigens, enabling a more physiologic assessment of tumor-immune cell interactions in immunocompetent hosts.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antigens
CRISPR-Cas Systems* / genetics
Genetic Therapy*
Humans
Iatrogenic Disease
Immunotherapy

Substances

Antigens

Abstract

Publication types

MeSH terms

Substances

Grants and funding